CanSino Biologics' (HKG:6185) new drug application for its Tetanus, Reduced Diphtheria, and Pertussis Combined Vaccine, Adsorbed, was granted priority review status by China's National Medical Products Administration.
The vaccine is a booster vaccine for diphtheria, tetanus, and acellular pertussis for adolescents and adults aged six years and above, according to a Monday Hong Kong bourse filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments